Back to today’s briefing

Story perspectives

Bayer Pharma Expects Growth Amid Patent Expirations

1/14/2026

45 10

Summary

Story summary

Bayer AG's pharmaceuticals unit expects growth as cancer and kidney drugs offset patent expirations.
CEO Bill Anderson of Bayer AG's pharmaceuticals unit aims to resolve Roundup litigation by 2026.
Stefan Oelrich, head of Bayer's pharma division, highlighted five promising drugs and forecast 2025 sales growth of flat to 3%.
Bayer's stock has nearly doubled in past year as it seeks revenue from Kerendia and Nubeqa and pursues asundexian.

1 of 1

Story summary

Bayer AG's pharmaceuticals unit expects growth as cancer and kidney drugs offset patent expirations.
CEO Bill Anderson of Bayer AG's pharmaceuticals unit aims to resolve Roundup litigation by 2026.
Stefan Oelrich, head of Bayer's pharma division, highlighted five promising drugs and forecast 2025 sales growth of flat to 3%.
Bayer's stock has nearly doubled in past year as it seeks revenue from Kerendia and Nubeqa and pursues asundexian.